目的 探讨美沙拉嗪联合白藜芦醇口服对溃疡性结肠炎的临床疗效及对炎症因子的影响。 方法 回顾性分析 2018 年 1 月至 2020 年 12 月复旦大学附属中山医院青浦分院收治的常规美沙拉嗪治疗的 56 例溃疡性结肠炎患者和白藜芦醇联合 治疗的 56 例溃疡性结肠炎患者。 连续治疗 8 周后,评估患者临床疗效、主要症状消失时间和治疗前后改良 Mayo 评分、Baron 内镜评分、疾病活动指数(DAI)、生活质量、焦虑及抑郁状态改善情况,并观察两组患者血清肿瘤坏死因子-α(TNF-α)、白细 胞介素-10(IL-10)、C 反应蛋白(CRP)和红细胞沉降率(ESR)变化情况。 结果 联合治疗组临床有效率 96. 42%(54 / 56)高于 对照组 83. 92%(47 / 56)(P= 0. 028)。 治疗后两组患者改良 Mayo 评分、Baron 内镜评分和 DAI 评分均明显低于治疗前,并且联 合治疗组 3 项评分均低于对照组,差异有统计学意义(P<0. 05)。 治疗后两组患者炎症性肠病生活质量问卷( IBDQ)评分、焦 虑和抑郁评分均优于治疗前,并且联合治疗组 3 项评分均低于对照组(P<0. 05)。 治疗后,两组患者血清 TNF-α、IL-10、CRP 和 ESR 水平均明显低于治疗前,并且联合治疗组血清 TNF-α、IL-10、CRP 和 ESR 水平均低于对照组,差异有统计学意义(P< 0. 05)。 结论 白藜芦醇补充治疗与轻中度溃疡性结肠炎患者的临床结局、生活质量和总体炎症水平改善显著相关。

Objective To investigate the clinical efficacy of resveratrol combined with mesalazine in the treatment of ulcerative colitis and the effect on inflammatory factors. Method A total of 112 UC patients admitted to Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University from January 2018 to December 2020 were selected. Patients were divided into mesalamine treatment group and mesalazine combined with resveratrol treatment group 56 patients each. Patients in both groups were treated for 8 weeks. After treatment the efficacy of the two groups colonoscopy scores disease activity index quality of life anxiety and depression status and serum tumor necrosis factor-α TNF-α interleukin-10 IL-10 C-reactive protein CRP and erythrocyte sedimentation rate ESR before and after treatment were observed and compared. Result The overall effective rate of the combined treatment group was 96. 42% 54 / 56 higher than that of the control group 83. 92% 47 / 56 P = 0. 028 . The modified Mayo score Baron endoscopic score and DAI score in both groups were lower than those before treatment. The 3 scores in the combined treatment group were lower than that of the control group with statistically significant difference P<0. 05 . After treatment the scores of IBDQ quality of life anxiety and depression in both groups were better than those before treatment and the 3 scores in the combined treatment group were lower than those of the control group P<0. 05 . After treatment the serum levels of TNF-α IL-10 CRP and ESR in both groups were lower than those before treatment and the level of TNF-α IL-10 CRP and ESR of the combined treatment group were significantly lower than those of the control group P< 0. 05 . Conclusion Resveratrol supplemental has a significant effect on the clinical outcomes quality of life and systemic inflammation in patients with mild to moderate ulcerative colitis.